越南儿童肺炎球菌结合疫苗对侵袭性肺炎球菌病的有效性:匹配病例对照研究
该研究在越南南部三家三级儿科医院开展匹配病例对照研究,纳入72例2-59月龄培养确诊侵袭性肺炎球菌病(IPD)住院患儿及288名年龄和社区匹配的对照。结果显示,PCV10对疫苗型IPD的调整疫苗有效性(VE)≥1剂为86.3%,PCV13对全部血清型IPD的调整VE≥1剂为84.4%,但非PCV10型IPD未见显著保护,且保护随时间推移而下降。
要点
- PCV10和PCV13对疫苗型IPD均显示高保护效力,支持越南国家引入。
- 血清型19A占主导(26.4%),应优先选择含19A的疫苗配方。
- 疫苗保护随时间下降,提示需加强针次安排。
核心结论
- PCV10和PCV13对越南幼儿疫苗型IPD和全部血清型IPD提供显著保护,尽管疫苗覆盖率低。
- 血清型19A占主导及保护随时间下降,强调选择含19A配方和加强免疫程序的重要性。
研究设计与样本
- 匹配病例对照研究,2022年2月至2025年1月在越南南部三家三级儿科医院开展。
- 病例为2-59月龄培养确诊IPD住院患儿,每例匹配4名年龄和社区对照,共72例病例和288名对照。
主要发现
- 37.5%的病例曾接种至少1剂PCV;最常见临床综合征为脑膜炎(36.1%)和肺炎相关脓毒症(30.6%)。
- 血清型19A最常见(26.4%),其次为6A(13.9%)和19F(11.1%);77.8%的病例由PCV13覆盖血清型引起。
- 针对疫苗型IPD,PCV10对PCV10型IPD的调整VE:≥1剂为86.3%(95%CI 13.3-97.9),≥2剂为89.5%(95%CI 16.1-98.7);PCV13对PCV13型IPD的VE同样高。
- 针对全部血清型IPD,调整VE:≥1剂PCV10为65.1%(95%CI 21.8-84.4),≥1剂PCV13为84.4%(95%CI 20.0-97.0)。
- 对非PCV10型IPD未见显著有效性;VE对血清型6A最高,并随接种后时间延长而下降。
临床怎么用
- 在越南国家引入PCV前,应优先选择含19A的疫苗配方并考虑加强免疫程序。
- 尽管疫苗覆盖率低,PCV10和PCV13仍显示对IPD的显著保护,支持及时引入。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Evidence on the effectiveness of pneumococcal conjugate vaccines (PCVs) in Vietnam remains limited, despite the availability of 10-valent (PCV10) and 13-valent (PCV13) conjugate vaccines in the private sector since 2014 and 2019. We evaluated the effectiveness of PCVs against invasive pneumococcal disease (IPD) among Vietnamese children prior to national introduction. METHODS: We conducted a matched case-control study between February 2022 and January 2025 in southern Vietnam. Cases were children aged 2-59 months hospitalized with culture-confirmed IPD from normally sterile sites at three tertiary pediatric hospitals. Four age- and neighborhood-matched community controls were enrolled per case. Vaccine effectiveness (VE) was estimated using conditional logistic regression as (1 - adjusted odds ratio) × 100%. RESULTS: We enrolled 72 IPD cases and 288 matched controls; 37.5% of cases had received ≥1 PCV dose. The most frequent clinical syndromes were meningitis (36.1%) and pneumonia-associated sepsis (30.6%). Serotype 19A predominated (26.4%), followed by 6A (13.9%) and 19F (11.1%); 77.8% of cases were caused by serotypes included in PCV13. For vaccine-type IPD (VT-IPD), adjusted VE of PCV10 against PCV10-type IPD was 86.3% (95% CI, 13.3-97.9) for ≥1 dose and 89.5% (95% CI, 16.1-98.7) for ≥2 doses; VE of PCV13 against PCV13-type IPD was similarly high. Against all-serotype IPD, adjusted VE was 65.1% (95% CI, 21.8-84.4) for ≥1 PCV10 dose and 84.4% (95% CI, 20.0-97.0) for ≥1 PCV13 dose. No significant effectiveness was observed against non-PCV10-type IPD. VE was highest against serotype 6 A and declined with increasing time since vaccination. CONCLUSIONS: This first Vietnamese evidence demonstrates that PCV10 and PCV13 provide substantial protection against VT-IPD and overall IPD in young children despite low vaccine coverage. The predominance of serotype 19A and waning protection over time emphasize the importance of selecting 19A-containing formulations and booster schedules to inform timely national PCV introduction in Vietnam.
引用
- Truong HC, Pham QD, Phan TV, et al. Effectiveness of pneumococcal conjugate vaccines against invasive pneumococcal disease in Vietnamese children prior to national introduction: A matched case-control study. Vaccine. 2026. PMID: 41702352. doi:10.1016/j.vaccine.2026.128349
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。